[Pharmacokinetics of cefotaxime and metabolites in uremic patients (author's transl)].
The study was done after a single dose in 6 normal subjects and 24 patients with varying degrees of renal insufficiency. In normal subjects, the results are similar whatever the assays are used. In uremic patients, the half-life for the terminal phase increased with renal failure with the microbioassay, but it is demonstrated that deacetyl cefotaxime has only a prolonged half - life with a more specific assay = HPLC method. After repetitive doses, the tendency for accumulation was only noted in patients with very severe renal failure (creatinine clearance less than 5 ml.min-1).
D000328:Adult; D000368:Aged; D001681:Biological Assay; D002439:Cefotaxime / Q000008:administration & dosage / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D003404:Creatinine / Q000378:metabolism; D004926:Escherichia coli / Q000378:metabolism; D006207:Half-Life; D006801:Humans; D007668:Kidney / Q000378:metabolism*; D007676:Kidney Failure, Chronic / Q000378:metabolism*; D008875:Middle Aged
D003404:Creatinine; D002439:Cefotaxime
Pharmacocinétique du céfotaxime et de ses métabolites chez les malades insuffisants rénaux.